Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma-Reference-Cited by-同舟云学术

Combination Anti-CTLA-4 and Anti-RANKL in Metastatic Melanoma

Published:2016-04-20 Issue:12 Volume:34 Page:e104-e106
ISSN:0732-183X
Container-title:Journal of Clinical Oncology
language:en
Short-container-title:JCO

Author:

Smyth Mark J.¹,Yagita Hideo²,McArthur Grant A.³

Affiliation:

1. Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria; Queensland Institute of Medical Research; School of Medicine, University of Queensland, Herston, Queensland, Australia

2. Juntendo University School of Medicine, Tokyo, Japan

3. Peter MacCallum Cancer Centre, East Melbourne; University of Melbourne, Parkville, Victoria

Publisher

American Society of Clinical Oncology (ASCO)

Subject

Cancer Research,Oncology

Link

https://ascopubs.org/doi/pdfdirect/10.1200/JCO.2013.51.3572

Reference10 articles.

1. Enhancement of Antitumor Immunity by CTLA-4 Blockade

2. Conditional Regulatory T-Cell Depletion Releases Adaptive Immunity Preventing Carcinogenesis and Suppressing Established Tumor Growth

3. Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

4. Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

5. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

Cited by 61 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting the NF-κB pathway as a potential regulator of immune checkpoints in cancer immunotherapy;Cellular and Molecular Life Sciences;2024-02-29

2. Immune Modulation with RANKL Blockade through Denosumab Treatment in Patients with Cancer;Cancer Immunology Research;2024-01-26

3. Spectrum of Treg and self-reactive T cells: single cell perspectives from old friend HTLV-1;Discovery Immunology;2024-01-01

4. Combination of immunotherapy, radiotherapy and denosumab as the best approach even for NSCLC poor prognosis patients: a case report with strong response, prolonged survival and a review of literature;Current Problems in Cancer;2023-12

5. Dacarbazine;Reactions Weekly;2023-11-11